Sugi Predict

Sugi Predict / Compounds / SCHEMBL2482618

SCHEMBL2482618

SCHEMBL2482618

Cc1nccn1-c1ccc(Nc2nc3c(c(NCC4CCOCC4)n2)CNCC3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNH3 Q9ULD8 1/20 0.39
▸ TNK2 Q07912 8/20 0.39
▸ SYK P43405 3/20 0.38
▸ TRPV1 Q8NER1 1/20 0.36
▸ LRRK2 Q5S007 2/20 0.36
▸ MET P08581 1/20 0.35
▸ AXL P30530 1/20 0.35
▸ MERTK Q12866 1/20 0.35
▸ JAK2 O60674 2/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ IGF1R P08069 1/20 0.35
▸ CHEK1 O14757 1/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ LCK P06239 1/20 0.35
▸ ROS1 P08922 1/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ SRC P12931 1/20 0.35
▸ TYK2 P29597 1/20 0.35
▸ ALK Q9UM73 1/20 0.35
▸ FLT3 P36888 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2476403 0.89 TNK2 (0.52) KCNH3TNK2JAK2CHEK1ABL1
SCHEMBL2484410 0.89 TNK2 (0.52) KCNH3TNK2JAK2CHEK1ABL1
SCHEMBL2476408 0.89 TNK2 (0.52) KCNH3TNK2JAK2CHEK1ABL1
SCHEMBL2480301 0.87 LRRK2 (0.39) TNK2SYKLRRK2JAK2IGF1R
SCHEMBL2448060 0.86 TRPV1 (0.40) KCNH3TNK2SYKTRPV1LRRK2
SCHEMBL13355536 0.83 SYK (0.39) TNK2SYKLRRK2METJAK2
SCHEMBL2447374 0.83 SYK (0.41) KCNH3TNK2SYKTRPV1LRRK2
SCHEMBL2843371 0.81 SYK (0.44) SYKJAK2JAK3TYK2
SCHEMBL2444641 0.80 SYK (0.39) SYKFGFR1SRC
SCHEMBL2843649 0.79 SYK (0.47) SYKTRPV1MERTKJAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 — — US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 — — US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 — — US disclosed
EP-2367826-A1 MODULATORS OF AMYLOID BETA. AstraZeneca AB (SE) 2011-09-28 — — EP disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 — — US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 — — US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 — — US disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 — — WO disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130495-A1 COMPOUNDS 563 BACE1, PSEN1, PSEN2 KCNH3 4816/4885TNK2 1455/4885SYK 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.